Study of Neuroblastoma Staging and Pathology
Author Information
Author(s): Ikeda H, Iehara T, Tsuchida Y, Kaneko M, Hata J, Naito H, Iwafuchi M, Ohnuma N, Mugishima H, Toyoda Y, Hamazaki M, Mimaya J, Kondo S, Kawa K, Okada A, Hiyama E, Suita S, Takamatsu H
Primary Institution: Gunma Children's Medical Center
Hypothesis
The clinical value of the International Neuroblastoma Staging System and Pathology Classification has not been fully studied in new patients.
Conclusion
The study found that younger patients with neuroblastoma have significantly higher survival rates compared to older patients, particularly when classified by INSS stage and histology.
Supporting Evidence
- The 4-year overall survival rate for patients <12 months with INSS stages 1, 2A, 2B, 3, and 4S was 98.5%.
- The survival rate for patients with favourable histology was significantly higher than for those with unfavourable histology.
- MYCN amplification was significantly associated with poor prognosis in both age groups.
- Statistical analysis showed significant differences in survival rates based on INSS stage and histology.
Takeaway
This study looked at kids with a type of cancer called neuroblastoma and found that younger kids tend to do much better than older kids when treated.
Methodology
The study retrospectively reviewed 731 patients with neuroblastoma treated between January 1995 and December 1999, analyzing survival rates based on INSS stage and histology.
Potential Biases
Potential bias due to the retrospective nature of the study and the exclusion of patients with insufficient data.
Limitations
The study was retrospective and may not account for all variables affecting survival.
Participant Demographics
The study included 368 males and 276 females, with a median age of 8 months.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website